Insider buying last 90 days
No open-market insider purchases were filed for ADMA in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ADMA insider filing, plotted on the chart in Gekko.Open ADMA in Gekko
NASDAQ: ADMA
ADMA Biologics (ADMA) Stock Analysis & Forecast
Oct 12 close
$10.18−0.18 (−1.7%)
Gekko Brief
AI summaryOct 12 closeThis week's attention on ADMA Biologics centers on analyst activity rather than company-specific news. Argus raised its target price for ADMA to $10.00, with the stock trading at $10.36 at the time of that note. Separately, the stock carries a "Moderate Buy" average rating from six research firms, and comparative coverage has placed ADMA alongside Myriad Genetics. Commentary also flagged upcoming earnings expectations, with analysts anticipating an 18.75% rise in EPS and 4.16% revenue growth for the next quarterly report.
ADMA closed at $10.18, down 1.7%, sitting between its 50-day average of $9.60 and 200-day average of $11.48. The GekkoIndex reads 50.5, placing the stock in the Neutral zone, with the index down 0.5 over five days. Shares trade 18.4% below Gekko Fair Value, which stands at $12.47. One-month returns show a 10.3% gain, three-month returns 14.8%, while the six-month return is -1.9% and the one-year return is -30.9%.
ADMA next reports earnings on 4 November 2026, after close, 23 days away and within a typical 20-trading-day holding window; the prior report on 5 August 2026 met EPS estimates at $0.16 and produced a 12.9% reaction, with an average absolute reaction of 9.4% across the last eight quarters. Seasonality from this point in the calendar has averaged a 7% gain over the next 20 trading days across 5 years, rising in 3 of them. No insider, Congress, or unusual options activity appears in the current windows, though one billionaire holder is recorded. Consensus analyst target sits at $17, implying 67% upside per that consensus.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
ADMA Biologics price vs fair value
Close $10.18200-day averageGekko Fair Value $12.47
ADMA Biologics quick facts
- Market cap
- $2.36B
- P/E ratio
- 14.8
- Forward P/E
- 9.8
- EPS, TTM
- $0.70
- Revenue, TTM
- $512.3M
- Profit margin
- 33%
- Dividend yield
- —
- Beta
- 0.69
- Volume
- 1.63M avg 3.39M
- 1-year return
- −30.9%
- Typical daily move
- ±4.1%
- Typical 20-day move
- ±10.2%
- 50-day average
- $9.60
- 200-day average
- $11.48
- Next earnings
- Nov 4 after close
- Shares outstanding
- 224.0M
ADMA Biologics swing-trade checklist
ADMA Biologics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $10.18 sits between the 50-day ($9.60) and 200-day ($11.48) averages, or the averages disagree.
See the chart - GekkoIndexmixed
50.5, Neutral
Reading 50.5 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
18.4% below
Price is 18.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Nov 4, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.0% on average
From this point in the calendar, the next 20 trading days averaged +7% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
ADMA Biologics stock chart and price history
ADMA Biologics closed at $10.18 on Oct 12, 2026, −30.9% over the past year, inside a 52-week range of $7.21 to $20.46.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +10.3%
- 3 months
- +14.8%
- 6 months
- −1.9%
- 1 year
- −30.9%
The full ADMA chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ADMA in Gekko
Follow ADMA Biologics through every session
Put ADMA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ADMA in GekkoFree for 7 days. No credit card required.
About ADMA Biologics
ADMA Biologics operates in the biopharmaceutical space, turning donated blood plasma into treatments for people with weakened immune systems or infectious disease exposure. Patients in the United States and other countries rely on its therapies. The company has built its name around BIVIGAM and ASCENIV, a pair of intravenous immune globulin therapies given to those with primary humoral immunodeficiency, as well as Nabi-HB, a treatment used right after someone has been exposed to Hepatitis B or similar risks.
Alongside these approved products, ADMA Biologics continues to research further plasma-based treatments, including immunoglobulin candidates meant to guard against and treat S. pneumonia infections. It runs its own plasma collection sites rather than relying solely on outside suppliers, and it gets its therapies to patients through a combination of distributors, sales representatives, specialty pharmacies, and other healthcare outlets.
The company traces back to 2004 and operates out of Ramsey, New Jersey. Investors can find its shares listed on the NASDAQ under the ticker ADMA.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- admabiologics.com
ADMA Biologics GekkoIndex: the smart money zone
ADMA Biologics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 50.5, in the Neutral zone, down 0.5 points over five sessions.
50.5Neutral
Down 0.5 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 22 | +1.2% | +1.6% |
| Accumulation | 269 | +0.4% | 0.0% |
| Neutral (current zone) | 309 | +1.1% | +4.9% |
| Distribution | 70 | +1.5% | +9.2% |
| Selling | 12 | +2.4% | +8.2% |
Average ADMA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the ADMA price, zone by zone.Track ADMA in Gekko
Is ADMA Biologics stock overvalued? Gekko Fair Value
ADMA Biologics trades 18.4% below Gekko Fair Value of $12.47, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what ADMA Biologics shares are worth, recalculated every trading day.
$12.47
Gekko Fair Value, Oct 10, 2026
18.4% Undervalued
At the end of Aug 2026 the price was 34.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ADMA in Gekko
ADMA Biologics insider and Congress trading
No open-market insider purchases were filed for ADMA Biologics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ADMA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ADMA, plotted on the chart in Gekko.Open ADMA in Gekko
Buybacks
ADMA Biologics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $25.05M
- As a share of market cap
- 1.06%
- Trailing four quarters
- $187.2M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds ADMA.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
ADMA Biologics earnings: next date and track record
ADMA Biologics reports on Nov 4, 2026, after the close (23 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 23 days away
- EPS estimate
- $0.20
- Revenue estimate
- $138.1M
3 of 8reports beat the EPS estimate
±9.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- ADMA Biologics reported strong Q2 2026 results driven by ASCENIV momentum, with June delivering the strongest sequential utilization growth since H1 2024. Growth was fueled by increased physician adoption, new patient starts, and higher utilization. BIVIGAM demand stabilized with sequential improvements. Real-world evidence from 127 PID patients showed statistically significant reductions in hospitalizations and antibiotic use post-ASCENIV initiation, strengthening the product's differentiated market position.
- Guidance
- Management indicated ASCENIV remains early in penetrating the later-line refractory primary immunodeficiency market, suggesting continued revenue growth runway. Disciplined pricing strategy prioritizes durable, profitable growth over discounting despite competitive standard IG market pressures.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $0.16 est $0.16 | $124.4M est $125.3M | +12.9% |
| May 6, 2026 | $0.17 est $0.20 | $114.5M est $140.0M | −17.4% |
| Feb 25, 2026 | $0.22 est $0.19 | $139.2M est $139.6M | −2.2% |
| Nov 5, 2025 | $0.16 est $0.16 | $134.2M est $139.8M | −4.1% |
| Aug 6, 2025 | $0.15 est $0.14 | $122.0M est $130.3M | −11.7% |
| May 7, 2025 | $0.14 est $0.16 | $114.8M est $121.8M | −8.3% |
| Mar 3, 2025 | $0.14 est $0.14 | $117.5M est $108.7M | +3.8% |
| Nov 7, 2024 | $0.15 est $0.13 | $119.8M est $113.4M | +15.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
ADMA Biologics stock forecast and analyst price targets
Analysts’ average 12-month price target for ADMA Biologics is $17.00, +67.0% from the last close, from 2 firms rating the stock in the last 90 days.
$17.00consensus 12-month target, +67.0% from the last close
Now $10.18Avg $17.00
Low $17High $18
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 6 | Canaccord Genuity | $18 | +76.8% |
| Jul 15 | Mizuho Securities | $17 | +67.0% |
+4.9%average 20-day move after past Neutral readings
+7.0%average move over the next 20 trading days in the last 5 years
±4.1%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
ADMA Biologics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, ADMA Biologics averaged +7.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.8% | 3 of 5 |
| Next 10 trading days | −0.7% | 3 of 5 |
| Next 15 trading days | +5.5% | 4 of 5 |
| Next 20 trading days | +7.0% | 3 of 5 |
| Next 30 trading days | +20.2% | 5 of 5 |
For scale, ADMA’s typical 20-trading-day move in either direction is about 10.2%.
ADMA Biologics market cap and key statistics
ADMA Biologics’s market cap is $2.36B, with a P/E ratio of 14.8 and revenue of $512.3M over the last twelve months.
Valuation
- Market cap
- $2.36B
- P/E ratio
- 14.8
- Forward P/E
- 9.8
- EPS, TTM
- $0.70
- Gekko Fair Value
- $12.47
Trading
- Volume
- 1.63M
- Avg volume, 20 days
- 3.39M
- 52-week high
- $20.46
- 52-week low
- $7.21
- Shares outstanding
- 224.0M
Financials
- Revenue, TTM
- $512.3M
- Profit margin
- 33%
- Return on equity
- 41.9%
- Quarterly earnings growth, YoY
- +14.3%
Risk and income
- Beta
- 0.69
- Typical daily move
- ±4.1%
- Typical 20-day move
- ±10.2%
ADMA Biologics stock news this week
6 headlines about ADMA Biologics from the past week, newest first, each linking to the publisher.
- Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?Zacks Investment Research, Oct 12
- ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical AnalysisDefense World, Oct 12
- ADMA Biologics Inc (ADMA) Stock ForecastsYahoo! Finance Canada, Oct 11
- Adma Biologics (ADMA) Advances While Market Declines: Some Information for InvestorsYahoo Finance UK, Oct 8
- ADMA Biologics Inc (ADMA) is Attracting Investor Attention: Here is What You Should KnowZacks Investment Research, Oct 8
- ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Moderate Buy” from AnalystsDefense World, Oct 5
ADMA Biologics peers
ADMA Biologics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
ADMA Biologics stock FAQ
What is ADMA Biologics’s market cap?
ADMA Biologics’s market cap is $2.36B at the Oct 12, 2026 close of $10.18, with 224.0M shares outstanding. The shares trade on a P/E ratio of 14.8.
What is the ADMA Biologics stock forecast?
The consensus analyst 12-month price target for ADMA Biologics is $17.00, +67.0% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is ADMA Biologics stock overvalued or undervalued?
On Gekko’s estimate ADMA Biologics is undervalued: the Oct 12, 2026 close of $10.18 is 18.4% below Gekko Fair Value of $12.47. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does ADMA Biologics report earnings next?
ADMA Biologics is expected to report on Nov 4, 2026, after the market closes (23 days away). Analysts expect earnings of $0.20 per share on revenue of $138.1M. ADMA Biologics beat the earnings estimate in 3 of its last 8 reports, moving 9.4% on average across the report.
What is ADMA Biologics’s 52-week high and low?
ADMA Biologics’s 52-week high is $20.46 and its 52-week low is $7.21; it closed at $10.18 on Oct 12, 2026, −30.9% over the past year. Over the last five years the shares peaked at $25.67 on Apr 28, 2025.
Is ADMA Biologics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See ADMA Biologics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.